Nicotine e-cigarettes helped more adult smokers stop smoking than nicotine patches or gum did, according to an updated Cochrane living review published August 26, 2026 in the Cochrane Database of Systematic Reviews. The review pooled 80 completed randomized trials and 29,861 participants, nine of those trials new to this update, and rated the result high-certainty evidence, which is Cochrane’s top grade.
Key takeaways
- Adult smokers given nicotine vapes were about 61% more likely to be off cigarettes at six months than those given nicotine replacement therapy (risk ratio 1.61), which works out to about 4 extra quitters per 100 people.
- Against nicotine-free vapes, nicotine vapes raised quit rates by about 34% (risk ratio 1.34), which works out to roughly 2 extra quitters per 100 people.
- Serious adverse events were rare in every group, and the evidence runs to six months, not years.
What the review found
The Cochrane team searched the literature through January 1, 2026 and included only randomized controlled trials of people who smoked. The main outcome was not smoking for at least six months.
Against nicotine replacement therapy, nicotine e-cigarettes raised quit rates by about 61% (risk ratio 1.61, 95% CI 1.23 to 2.12), an effect very likely somewhere between 23% and 112% higher. That comparison drew on 11 trials and 4,114 participants. In absolute terms the authors write that this “might translate to an additional four quitters per 100 (95% CI 1 to 7 more).”
Against nicotine-free vapes, nicotine vapes raised quit rates by about 34% (risk ratio 1.34, 95% CI 1.05 to 1.69), or roughly two more quitters per 100, from 7 trials and 1,918 people. Cochrane graded that moderate certainty because the estimate is imprecise.
Nicotine vapes also outperformed behavioral support alone or no support, by about 75% (risk ratio 1.75), but the authors graded that comparison low certainty because of risk of bias built into those study designs.
On safety, serious adverse events were rare across all study arms, and rates were probably similar between nicotine vapes and nicotine replacement therapy. The most common side effects were throat and mouth irritation, headache, cough, and nausea, which the review says “tended to dissipate with continued EC use.”
Dr. Kumar’s take
Two separate questions keep getting merged in the coverage, and they have different answers.
This review is about adult smokers switching off cigarettes. It says nothing about teenagers who never smoked. For an adult already inhaling combustion products every day, swapping to a regulated nicotine device is a step down in exposure. For someone who has never smoked, there is no baseline exposure to step down from, so that trade does not exist at all. A result can be strong for one group and irrelevant to the other, the same way cold water swimming has real benefits and real risks depending on who is doing it.
Three things “high certainty” does not cover here.
Follow-up is six months, not five years. That is the standard cessation endpoint, and it is a real one, but it is not a statement about what daily vaping does to lungs or arteries over a decade.
The trials tested regulated nicotine devices, mostly given out with some study contact. Cochrane says so directly: illicit products, or products containing other active substances such as THC, may have different harm profiles. A disposable bought at a gas station is not the product that was studied.
The outcome measured is quitting smoking, not quitting nicotine. Someone who trades a pack a day for a vape counts as a success here, and by the logic of harm reduction that is a win. It is still a different thing from being free of the drug.
One more piece of context on the numbers: Cochrane rated 41 of the 80 included trials at high risk of bias overall and only 12 at low risk. And the size of the win against patches and gum is four extra quitters per 100. This moves the odds. It does not solve the problem.
What it means for you
If you smoke and you have already tried patches or gum without success, this is reasonable evidence that a regulated nicotine e-cigarette is a better tool for the specific job of stopping cigarettes, and that serious short-term harms were uncommon in the trials. Buy a regulated product, not an unknown one.
If you do not smoke, none of this is an argument to start. The benefit measured here comes entirely from what you stop doing.
If you have a teenager who vapes, this review is not reassurance. It was not designed to answer that question, and the researchers do not claim it was.